S&P 500   4,512.67 (+0.58%)
DOW   35,403.63 (+0.41%)
QQQ   374.74 (+0.56%)
AAPL   148.60 (+1.40%)
MSFT   308.18 (+0.29%)
FB   339.05 (+1.11%)
GOOGL   2,855.67 (+0.00%)
TSLA   871.05 (+0.11%)
AMZN   3,434.40 (-0.36%)
NVDA   221.74 (-0.22%)
BABA   173.79 (+4.18%)
NIO   39.93 (+0.81%)
CGC   13.46 (+1.97%)
GE   104.77 (+0.62%)
AMD   116.17 (-0.22%)
MU   67.03 (-0.34%)
T   25.43 (+0.39%)
F   15.55 (-0.06%)
ACB   6.98 (+0.87%)
DIS   170.34 (-0.47%)
PFE   42.14 (+1.98%)
BA   216.55 (-0.20%)
AMC   42.59 (-1.02%)
S&P 500   4,512.67 (+0.58%)
DOW   35,403.63 (+0.41%)
QQQ   374.74 (+0.56%)
AAPL   148.60 (+1.40%)
MSFT   308.18 (+0.29%)
FB   339.05 (+1.11%)
GOOGL   2,855.67 (+0.00%)
TSLA   871.05 (+0.11%)
AMZN   3,434.40 (-0.36%)
NVDA   221.74 (-0.22%)
BABA   173.79 (+4.18%)
NIO   39.93 (+0.81%)
CGC   13.46 (+1.97%)
GE   104.77 (+0.62%)
AMD   116.17 (-0.22%)
MU   67.03 (-0.34%)
T   25.43 (+0.39%)
F   15.55 (-0.06%)
ACB   6.98 (+0.87%)
DIS   170.34 (-0.47%)
PFE   42.14 (+1.98%)
BA   216.55 (-0.20%)
AMC   42.59 (-1.02%)
S&P 500   4,512.67 (+0.58%)
DOW   35,403.63 (+0.41%)
QQQ   374.74 (+0.56%)
AAPL   148.60 (+1.40%)
MSFT   308.18 (+0.29%)
FB   339.05 (+1.11%)
GOOGL   2,855.67 (+0.00%)
TSLA   871.05 (+0.11%)
AMZN   3,434.40 (-0.36%)
NVDA   221.74 (-0.22%)
BABA   173.79 (+4.18%)
NIO   39.93 (+0.81%)
CGC   13.46 (+1.97%)
GE   104.77 (+0.62%)
AMD   116.17 (-0.22%)
MU   67.03 (-0.34%)
T   25.43 (+0.39%)
F   15.55 (-0.06%)
ACB   6.98 (+0.87%)
DIS   170.34 (-0.47%)
PFE   42.14 (+1.98%)
BA   216.55 (-0.20%)
AMC   42.59 (-1.02%)
S&P 500   4,512.67 (+0.58%)
DOW   35,403.63 (+0.41%)
QQQ   374.74 (+0.56%)
AAPL   148.60 (+1.40%)
MSFT   308.18 (+0.29%)
FB   339.05 (+1.11%)
GOOGL   2,855.67 (+0.00%)
TSLA   871.05 (+0.11%)
AMZN   3,434.40 (-0.36%)
NVDA   221.74 (-0.22%)
BABA   173.79 (+4.18%)
NIO   39.93 (+0.81%)
CGC   13.46 (+1.97%)
GE   104.77 (+0.62%)
AMD   116.17 (-0.22%)
MU   67.03 (-0.34%)
T   25.43 (+0.39%)
F   15.55 (-0.06%)
ACB   6.98 (+0.87%)
DIS   170.34 (-0.47%)
PFE   42.14 (+1.98%)
BA   216.55 (-0.20%)
AMC   42.59 (-1.02%)
NASDAQ:INBX

Inhibrx Stock Forecast, Price & News

$40.35
+0.53 (+1.33 %)
(As of 10/19/2021 11:20 AM ET)
Add
Compare
Today's Range
$39.03
$40.48
50-Day Range
$26.75
$40.00
52-Week Range
$14.27
$50.97
Volume1,671 shs
Average Volume176,588 shs
Market Capitalization$1.53 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.26
30 days | 90 days | 365 days | Advanced Chart
Receive INBX News and Ratings via Email

Sign-up to receive the latest news and ratings for Inhibrx and its competitors with MarketBeat's FREE daily newsletter.


Inhibrx logo

About Inhibrx

Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. Its therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 1 clinical trials in patients with solid tumors, including sarcoma; and INBRX-105, an tetravalent conditional agonist of programmed death ligand 1 (PD-L1) and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with PD-L1 expressing tumors. The company's therapeutic candidates also comprise INBRX-101, an Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with alpha-1 antitrypsin deficiency. Its preclinical programs include INBRX-106, a single domain antibody based hexavalent agonist of OX40 for a range of oncology indications. Inhibrx, Inc. was founded in 2010 and is headquartered in La Jolla, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:INBX
Employees
88
Year Founded
N/A

Sales & Book Value

Annual Sales
$12.89 million
Book Value
$2.00 per share

Profitability

Net Income
$-76.12 million
Net Margins
-742.82%

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$1.53 billion
Next Earnings Date
11/12/2021 (Estimated)
Optionable
Not Optionable

MarketRank

Overall MarketRank

1.98 out of 5 stars

Medical Sector

611th out of 1,361 stocks

Biological Products, Except Diagnostic Industry

94th out of 196 stocks

Analyst Opinion: 2.5Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -












Inhibrx (NASDAQ:INBX) Frequently Asked Questions

Is Inhibrx a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Inhibrx in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Inhibrx stock.
View analyst ratings for Inhibrx
or view top-rated stocks.

What stocks does MarketBeat like better than Inhibrx?

Wall Street analysts have given Inhibrx a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Inhibrx wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Inhibrx?

Inhibrx saw a decrease in short interest during the month of August. As of August 31st, there was short interest totaling 808,900 shares, a decrease of 20.7% from the August 15th total of 1,020,000 shares. Based on an average daily trading volume, of 201,600 shares, the days-to-cover ratio is currently 4.0 days. Approximately 3.6% of the company's shares are sold short.
View Inhibrx's Short Interest
.

When is Inhibrx's next earnings date?

Inhibrx is scheduled to release its next quarterly earnings announcement on Friday, November 12th 2021.
View our earnings forecast for Inhibrx
.

How were Inhibrx's earnings last quarter?

Inhibrx, Inc. (NASDAQ:INBX) announced its earnings results on Monday, August, 9th. The company reported ($0.55) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.56) by $0.01. The firm had revenue of $0.95 million for the quarter, compared to the consensus estimate of $0.90 million. Inhibrx had a negative trailing twelve-month return on equity of 114.87% and a negative net margin of 742.82%.
View Inhibrx's earnings history
.

What price target have analysts set for INBX?

2 Wall Street analysts have issued 1 year target prices for Inhibrx's stock. Their forecasts range from $44.00 to $46.00. On average, they expect Inhibrx's share price to reach $45.00 in the next year. This suggests a possible upside of 11.5% from the stock's current price.
View analysts' price targets for Inhibrx
or view top-rated stocks among Wall Street analysts.

Who are Inhibrx's key executives?

Inhibrx's management team includes the following people:
  • Mr. Mark Paul Lappe, Founder, Chairman, Pres & CEO (Age 53, Pay $868.96k)
  • Dr. Brendan P. Eckelman, Founder, Chief Scientific Officer, Exec. VP of Corp. Strategy & Director (Age 41, Pay $589.75k) (LinkedIn Profile)
  • Dr. Klaus W. Wagner, Chief Medical Officer & Exec. VP (Age 48, Pay $600.07k)
  • Mr. Quinn L. Deveraux, Founder
  • Ms. Kelly Devine Deck B.S., CPA, M.S., Chief Financial Officer (Age 40)
  • Dr. Ashraf Amanullah, Exec. VP & Chief Technical Operations Officer (Age 53)
  • Ms. Leah Pollema J.D., VP, Corp. Sec. & Gen. Counsel
  • Ms. Analeah Heidt Ph.D., Exec. VP of Translational Research
  • Mr. Jeffrey J. Jensen, Exec. VP of Clinical Operations

What other stocks do shareholders of Inhibrx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Inhibrx investors own include Advanced Micro Devices (AMD), Trevena (TRVN), Vivint Solar (VSLR), (APHA), Activision Blizzard (ATVI), Daqo New Energy (DQ), Fastly (FSLY), Innovative Industrial Properties (IIPR), The Lovesac (LOVE) and Micron Technology (MU).

When did Inhibrx IPO?

(INBX) raised $102 million in an initial public offering on Wednesday, August 19th 2020. The company issued 6,000,000 shares at $16.00-$18.00 per share. Jefferies, Evercore ISI and Credit Suisse served as the underwriters for the IPO and LifeSci Capital was co-manager.

What is Inhibrx's stock symbol?

Inhibrx trades on the NASDAQ under the ticker symbol "INBX."

How do I buy shares of Inhibrx?

Shares of INBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Inhibrx's stock price today?

One share of INBX stock can currently be purchased for approximately $40.35.

How much money does Inhibrx make?

Inhibrx has a market capitalization of $1.53 billion and generates $12.89 million in revenue each year. The company earns $-76.12 million in net income (profit) each year or ($3.01) on an earnings per share basis.

How many employees does Inhibrx have?

Inhibrx employs 88 workers across the globe.

What is Inhibrx's official website?

The official website for Inhibrx is www.inhibrx.com.

Where are Inhibrx's headquarters?

How can I contact Inhibrx?

Inhibrx's mailing address is 11025 N. TORREY PINES ROAD SUITE 200, LA JOLLA CA, 92037. The company can be reached via phone at 858-795-4220 or via email at [email protected].


This page was last updated on 10/19/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.